Clinical Trial Update: Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial studying miricorilant for nonalcoholic steatohepatitis (NASH) has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• Miricorilant (CORT118335)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: TERMINATED | Results posted: 2022-08-31